Sorrento And Mount Sinai Jointly Develop COVID-19 Antibody Therapy

Sorrento Therapeutics and the Mount Sinai Health System are collaborating to develop an antibody cocktail that could treat COVID-19.

The COVI-SHIELD cocktail would be administered as often as necessary, with each dose expected to provide antiviral protection for up to two months.

The partners anticipate the therapy will be offered as a prophylactic for those returning to work and as a therapeutic to those who have been exposed to SARS-CoV-2.